Halozyme Therapeutics HALO Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's cash provided by (used in) financing activity, including discontinued operation?
- Halozyme Therapeutics (HALO) reported cash provided by (used in) financing activity, including discontinued operation of -$1.61M in Q1 2026.
- How has Halozyme Therapeutics's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Halozyme Therapeutics's cash provided by (used in) financing activity, including discontinued operation increased by 51.4% year-over-year, from -$3.32M to -$1.61M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.